Clinigen Group PLC (LON:CLIN) has taken a “first significant step” to revitalise its Proleukin drug by agreeing to supply the product to an American life sciences company developing exciting new cancer immunotherapies.
Iovance Biotherapeutics is carrying out pivotal studies of its tumour infiltrating lymphocytes (TIL) technology on head, neck and lung patients with advanced forms of the killer disease.
Proleukin, currently used to treat liver and skin cancer, is part of the TIL therapy treatment regimen being assessed.
As such, it will be made available by Clinigen in bulk supply over a two-year period so Iovance has uninterrupted access for its clinical trials.
Chief executive Shaun Chilton said: “Proleukin is the only approved IL-2 in the US and Europe that is currently being used in TIL therapy development and is an inherent component of these programs. This is a product that is involved in over 80 clinical trials in the US alone, which presents other similar opportunities for us to pursue.”